At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Varenicline for the Treatment of Smokeless Tobacco Use
In Brief
A clinical study evaluating varenicline and placebo for Nicotine Dependence. Completed, enrolled 76 participants across 1 site.
Detailed Summary
Varenicline (Chantix™, Pfizer) is a novel selective nicotinic receptor partial agonist with specificity for the α4β2 nicotine acetylcholine receptor that has demonstrated remarkable efficacy for increasing long-term tobacco abstinence rates in cigarette smokers. The novel mechanism of action of varenicline potentially circumvents the limitations of using nicotine replacement therapy or bupropion pharmacotherapy in ST users. The overall goal of this line of research is to develop effective pharmacologic treatments for ST users to increase long-term (≥ 6 months) abstinence rates. The central hypothesis of this application is that varenicline is efficacious for the treatment of ST users.
Study Details
Timeline
Interventions
12 weeks of varenicline 1 mg by mouth twice per day
12 weeks of placebo (double blinded) by mouth twice per day